N4 Pharma (GB:N4P) has released an update.
N4 Pharma PLC has announced a significant advancement in their Nuvec® delivery system with successful chemistry work completed by SRI International, enabling specific cell targeting for nucleic acid programs. This innovation allows Nuvec® to integrate a Molecular Guidance System without impacting its loading capabilities, paving the way for targeted siRNA delivery in cancer treatments, gene therapies, and vaccines. The company is now preparing to market this breakthrough to major pharmaceutical and biotech companies.
For further insights into GB:N4P stock, check out TipRanks’ Stock Analysis page.
